<DOC>
	<DOCNO>NCT00930098</DOCNO>
	<brief_summary>This study population patient alternative option conduct determine response rate clofarabine . Additionally study provide information safety profile , impact overall survival , impact remission duration clofarabine . It single arm study comparator .</brief_summary>
	<brief_title>A Phase II , Open-Label Study Clofarabine Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia</brief_title>
	<detailed_description>Note : This clinical trial conduct Bioenvision Ltd. Bioenvision Ltd. acquire Genzyme Corporation Oct 2007 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Have diagnosis ALL confirm pathologic assessment . Be ≤ 21 year old time initial diagnosis . Eligible patient must : Primary refractory disease ; OR relapse refractory disease minimum 2 prior block treatment . Must eligible therapy higher curative potential . Have Karnofsky Performance Status ≥ 50 Lansky Performance Scale ≥ 30 . Provide sign , write informed consent parent guardian young adult patient . Be able comply study procedure followup examination . Have adequate cardiac function without treatment . Have adequate organ function indicate laboratory value serum creatinine , serum bilirubin , AST ALT , obtain within 7 day prior registration . Received previous treatment clofarabine . Patients isolated extramedullary disease . Have receive prior BMT PBSCT within last 6 month . Have receive prior BMT PBSCT 6 month ago , compromise organ function . Have active , uncontrolled systemic infection . Are pregnant lactate . Male female patient fertile must agree use effective mean birth control avoid pregnancy . Have psychiatric disorder would interfere consent , study participation , followup . Have receive chemotherapy within previous 2 week must recover acute toxicity oa previous therapy prior enrollment . Have severe concurrent disease . Have recent history significant renal , hepatic pulmonary dysfunction , cardiac dysfunction treatment support cardiac function . Have CNS disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>clolar</keyword>
	<keyword>evoltra</keyword>
	<keyword>clofarabine</keyword>
	<keyword>refractory/relapsed acute leukemia</keyword>
	<keyword>pediatric acute leukemia</keyword>
</DOC>